CR20210515A - Extractos bacterianos estables como fármacos - Google Patents

Extractos bacterianos estables como fármacos

Info

Publication number
CR20210515A
CR20210515A CR20210515A CR20210515A CR20210515A CR 20210515 A CR20210515 A CR 20210515A CR 20210515 A CR20210515 A CR 20210515A CR 20210515 A CR20210515 A CR 20210515A CR 20210515 A CR20210515 A CR 20210515A
Authority
CR
Costa Rica
Prior art keywords
novel
bacterial extracts
drugs
stable bacterial
stable
Prior art date
Application number
CR20210515A
Other languages
English (en)
Inventor
Jacques Bauer
Christian Pasquali
Original Assignee
Om Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Om Pharma Sa filed Critical Om Pharma Sa
Publication of CR20210515A publication Critical patent/CR20210515A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/08—Reducing the nucleic acid content
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se relaciona con preparaciones de extractos bacterianos estables novedosas que tienen estabilidad sustancialmente incrementada con el tiempo, métodos novedosos de preparación de las mismas, formulaciones farmacéuticas basadas en los extractos bacterianos estabilizados novedosos, así como rutas novedosas de administración y dispositivos de liberación para tratar y/o prevención de trastornos inmunológicos agudos y crónicos resultantes de infecciones y/o inflamación y/o neoplasmas y/o disbiosis.
CR20210515A 2019-03-14 2020-03-12 Extractos bacterianos estables como fármacos CR20210515A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19162912 2019-03-14
PCT/EP2020/056742 WO2020182970A1 (en) 2019-03-14 2020-03-12 Process for making stable bacterial extracts and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
CR20210515A true CR20210515A (es) 2022-03-28

Family

ID=65991511

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210515A CR20210515A (es) 2019-03-14 2020-03-12 Extractos bacterianos estables como fármacos

Country Status (24)

Country Link
US (3) US11801271B2 (es)
EP (3) EP3937957B1 (es)
JP (2) JP2022525177A (es)
KR (1) KR102922470B1 (es)
CN (1) CN113840615A (es)
AU (1) AU2020235261B2 (es)
BR (1) BR112021018006A2 (es)
CA (1) CA3132564A1 (es)
CL (1) CL2021002401A1 (es)
CO (1) CO2021013677A2 (es)
CR (1) CR20210515A (es)
CU (1) CU20210077A7 (es)
ES (1) ES3073031T3 (es)
IL (1) IL286215B2 (es)
MA (1) MA55291B1 (es)
MX (1) MX2021010912A (es)
PE (1) PE20212261A1 (es)
PH (1) PH12021552089A1 (es)
PL (1) PL3937957T3 (es)
RS (1) RS68244B1 (es)
SG (1) SG11202109937UA (es)
SM (1) SMT202600259T1 (es)
WO (1) WO2020182970A1 (es)
ZA (1) ZA202106914B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020182322A1 (en) * 2019-03-14 2020-09-17 Om Pharma Sa Method of treating and/or preventing asthma, asthma exacerbations, allergic asthma and/or associated conditions with microbiota related to respiratory disorders
TW202304485A (zh) * 2021-04-12 2023-02-01 香港中文大學 用於增強免疫力的方法和組合物
KR20220152156A (ko) * 2021-05-07 2022-11-15 시므라이즈 아게 락토바실러스 종의 신규한 박테리아 발효물
WO2022233441A1 (en) * 2021-05-07 2022-11-10 Symrise Ag Novel bacterial ferment of lactobacillus species
EP4134426A1 (en) * 2021-08-13 2023-02-15 Symrise AG Novel bacterial ferment of lactobacillus species
CN118475359A (zh) * 2021-12-22 2024-08-09 株式会社明治 用于预防继发感染症或用于降低继发感染症发生风险的组合物
KR102763094B1 (ko) * 2022-12-09 2025-02-12 대한민국 혈관 염증 완화에 효과적인 식용 곰팡이 균주의 가수분해 물질의 제조 방법
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
CN118460405B (zh) * 2024-04-26 2025-03-04 广东悦创生物科技有限公司 一株副干酪乳酪杆菌xy6及其在制备调理肠胃和减肥药品中的应用
CN121427776B (zh) * 2025-12-26 2026-04-10 威凯海思(山东)生物工程有限公司 一株罗伊氏粘液乳杆菌hc1602及其菌剂和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
SK280968B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Balenie medikamentu na použite v inhalačnom prístroji
CH685498A5 (fr) 1992-02-14 1995-07-31 Om Lab Sa Extrait de macromolécules bactériennes, procédé pour sa préparation et composition pharmaceutique contenant cet extrait.
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
US7171965B2 (en) 2000-02-01 2007-02-06 Valois S.A.S. Breath actuated dry powder inhaler and tape dose strip
US6994083B2 (en) 2001-12-21 2006-02-07 Trudell Medical International Nebulizer apparatus and method
WO2006060282A2 (en) * 2004-11-30 2006-06-08 Merial Limited Mixing devices for chemical lysis of cells
WO2008085549A2 (en) * 2006-07-28 2008-07-17 Board Of Regents Of The University Of Texas System Compositions and methods for stimulation of lung innate immunity
PL2117587T3 (pl) * 2007-03-05 2018-07-31 Om Pharma Ekstrakt bakteryjny przeznaczony do stosowania względem zaburzeń układu pokarmowego lub moczowego i sposób jego wytwarzania
AU2008222865B2 (en) * 2007-03-05 2013-01-31 Om Pharma Bacterial extract for respiratory disorders and proces for its preparation
FR2923491B1 (fr) * 2007-11-14 2012-12-14 Deinove Sa Utilisation de bacteries pour la production de sources de bioenergie
GB0818453D0 (en) * 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
ES2356883B1 (es) 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
AU2008361375B2 (en) * 2008-09-04 2014-05-22 Om Pharma Immunomodulatory extracts from Lactobacillus bacteria and methods of manufacturing and use thereof
RU2425691C1 (ru) 2010-07-15 2011-08-10 ВАКЕ спол с.р.о. Аэрозольный препарат на основе апротинина для лечения вирусных респираторных инфекций
US9132243B2 (en) * 2010-07-23 2015-09-15 Tannermedico A/S Method of administering a substance to the throat
CN101979541A (zh) * 2010-10-28 2011-02-23 徐堤 一种快速共价闭合环状dna纯化试剂盒
JP2014528458A (ja) * 2011-10-07 2014-10-27 アンピオ ファーマシューティカルズ，インコーポレイテッド 鼻炎の治療
CA3045079A1 (en) * 2016-12-13 2018-06-21 Defensin Therapeutics Aps Methods for treating inflammatory conditions of the lungs

Also Published As

Publication number Publication date
RS68244B1 (en) 2026-07-31
MA55291A (fr) 2022-01-19
US20210401902A1 (en) 2021-12-30
CN113840615A (zh) 2021-12-24
KR102922470B1 (ko) 2026-02-03
CO2021013677A2 (es) 2021-10-20
US20230346855A1 (en) 2023-11-02
EP3937957A1 (en) 2022-01-19
ES3073031T3 (en) 2026-07-07
CU20210077A7 (es) 2022-04-07
KR20210141546A (ko) 2021-11-23
IL286215B1 (en) 2025-04-01
MA55291B1 (fr) 2026-06-30
US20250195587A1 (en) 2025-06-19
MX2021010912A (es) 2021-10-01
BR112021018006A2 (pt) 2021-11-16
WO2020182970A1 (en) 2020-09-17
JP2025176089A (ja) 2025-12-03
US11801271B2 (en) 2023-10-31
ZA202106914B (en) 2023-10-25
CA3132564A1 (en) 2020-09-17
SG11202109937UA (en) 2021-10-28
EP4721819A3 (en) 2026-06-10
EP4234026A3 (en) 2024-07-03
IL286215B2 (en) 2025-08-01
PH12021552089A1 (en) 2022-05-23
EP4721819A2 (en) 2026-04-08
EP4234026A2 (en) 2023-08-30
AU2020235261B2 (en) 2026-04-30
EP3937957C0 (en) 2026-05-06
PL3937957T3 (pl) 2026-08-03
SMT202600259T1 (it) 2026-07-16
EP3937957B1 (en) 2026-05-06
AU2020235261A1 (en) 2021-09-16
PE20212261A1 (es) 2021-11-29
IL286215A (en) 2021-10-31
JP2022525177A (ja) 2022-05-11
CL2021002401A1 (es) 2022-04-08

Similar Documents

Publication Publication Date Title
CL2021002401A1 (es) Extractos bacterianos estables como fármacos
CO2018013654A2 (es) Composiciones nasales de cannabidiol
CL2020000747A1 (es) Formulaciones de niraparib.
CO2019000643A2 (es) Formulaciones gastrorretentivas orales y usos de las mismas
BR112019001852A2 (pt) composição de cannabis
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
CL2019002745A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
BR112017008301A2 (pt) extratos de cannabis e métodos de sua preparação e uso
CL2019003309A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2019002744A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2019003294A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
MX387442B (es) Composiciones y tratamientos para el trastorno del sueño
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
CO2018009563A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
BR112018073663A2 (pt) moduladores de receptores nmda spiro-lactâmicos e seus usos
MX2017011830A (es) Fitocomplejos que exhiben actividades antioxidantes sinergicas, multiples, utiles en alimentos, suplementos alimenticios, cosmeticos y preparaciones farmaceuticas.
MX2020008017A (es) Formulaciones de vidrio y usos de las mismas.
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
MX2019001633A (es) Proteina derivada de la seda para el tratamiento de la inflamacion.
MX2019001322A (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
CL2018003502A1 (es) Métodos para tratar la osificación heterotópica.
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.